Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Faxeladol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.48 |
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Faxeladol SCHEMBL5393347 | 1.00 | SLC6A4 (0.48) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL7882332 | 0.99 | SLC6A4 (0.49) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL465057 | 0.99 | SLC6A4 (0.49) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL465056 | 0.99 | SLC6A4 (0.49) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL7893759 | 0.99 | SLC6A4 (0.49) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL149508 | 0.97 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL28793358 | 0.97 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL30616185 | 0.97 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL354208 | 0.97 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 | |
| Faxeladol SCHEMBL5686250 | 0.97 | SLC6A4 (0.50) | SLC6A4SLC6A2OPRM1MEN1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499582-B1 | METHOD FOR CHLORINATING TERTIARY ALCOHOLS | GRUENENTHAL GMBH (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-7235693-B2 | Process for chlorinating tertiary alcohols | GRUENENTHAL GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20070142681-A1 | Process for chlorinating tertiary alcohols | GRUENENTHAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20050119349-A1 | Process for chlorinating tertiary alcohols | GRUENENTHAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1499582-A1 | METHOD FOR CHLORINATING TERTIARY ALCOHOLS | Grünenthal GmbH (DE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003091199-A1 | METHOD FOR CHLORINATING TERTIARY ALCOHOLS | Grünenthal GmbH (DE) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119349-A1 | Process for chlorinating tertiary alcohols | ADH1C, ADH5, ADH1A | SLC6A4 2388/4885SLC6A2 3649/4885OPRM1 446/4885 |
| US-20070142681-A1 | Process for chlorinating tertiary alcohols | ADH1C, ADH1A, ADH5 | SLC6A4 2790/4885SLC6A2 3926/4885OPRM1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.